![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
BMS-955176: Antiviral Activity and Safety of a Second-Generation HIV-1 Maturation Inhibitor
|
|
|
Reported by Jules Levin
CROI 2015 Feb 23-26 Seattle, WA
Carey Hwang,1 Dirk Schurmann,2 Christian Sobotha,2 Heather Sevinsky,1
Palanikumar Ravindran,1 Hong Xiao,1 Neelanjana Ray,1 Mark Krystal,3 Ira Dicker3 and Max Lataillade3, on behalf of the BMS HIV Development Team
1 Bristol-Myers Squibb, Research and Development, Princeton, NJ, USA
2 Charite Research Organisation GmbH, Chariteplatz 1, 10117 Berlin, Germany
3 Bristol-Myers Squibb, Research and Development, Wallingford, CT, USA
Webcast
http://www.croiwebcasts.org/console/player/25756?mediaType=slideVideo&
![CROI1.gif](../images/022715/022715-6/CROI1.gif)
![CROI2.gif](../images/022715/022715-6/CROI2.gif)
![CROI3.gif](../images/022715/022715-6/CROI3.gif)
![CROI4.gif](../images/022715/022715-6/CROI4.gif)
![CROI5.gif](../images/022715/022715-6/CROI5.gif)
![CROI6.gif](../images/022715/022715-6/CROI6.gif)
![CROI7.gif](../images/022715/022715-6/CROI7.gif)
![CROI8.gif](../images/022715/022715-6/CROI8.gif)
![CROI9.gif](../images/022715/022715-6/CROI9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|